Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of “Buy” from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has received an average recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $10.00.

IPSC has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Chardan Capital decreased their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Guggenheim reissued a “buy” rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Finally, Piper Sandler decreased their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research report on Monday, December 30th.

Century Therapeutics Trading Down 3.4 %

Shares of IPSC stock opened at $0.85 on Wednesday. Century Therapeutics has a 1 year low of $0.83 and a 1 year high of $5.51. The firm’s fifty day moving average price is $1.15 and its two-hundred day moving average price is $1.51. The firm has a market capitalization of $71.85 million, a P/E ratio of -0.46 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The firm had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. During the same period in the previous year, the business earned ($0.55) EPS. As a group, equities research analysts forecast that Century Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Trading of Century Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its holdings in shares of Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after buying an additional 9,500 shares during the period. SG Americas Securities LLC bought a new stake in shares of Century Therapeutics during the 3rd quarter worth about $27,000. Rhumbline Advisers boosted its holdings in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after buying an additional 18,828 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after buying an additional 32,614 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after buying an additional 44,155 shares during the period. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.